FENNEC PHARMACEUTICALS INC (FRX.CA) Stock Analyst Ratings
Canada - Toronto Stock Exchange - TSX:FRX - CA31447P1009 - Common Stock
10.63 CAD
+0.24 (+2.31%)
ChartMill assigns a Buy % Consensus number of 85% to FRX.CA. The Buy consensus is the weighted average rating of the current analysts ratings.
FRX.CA was analyzed by 11 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about FRX.CA.
In the previous month the buy percentage consensus was at a similar level.
FRX.CA was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-11-23 | Cantor Fitzgerald Securities | Upgrade | Overweight |
| 2021-06-03 | HC Wainwright & Co. | Maintains | Buy |
| 2021-04-21 | Craig-Hallum | Initiate | Buy |
| 2021-04-19 | Maxim Group | Initiate | Buy |
FENNEC PHARMACEUTICALS INC / FRX.CA FAQ
What is the consensus rating for FENNEC PHARMACEUTICALS INC (FRX.CA) stock?
The consensus rating for FENNEC PHARMACEUTICALS INC (FRX.CA) is 85.4545 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for FRX stock?
The number of analysts covering FENNEC PHARMACEUTICALS INC (FRX.CA) is 11.